Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PPOX | P50336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740405 | 1.00 | POLB (0.64) | POLBHPGDL3MBTL1ALDH1A1LTA4H | |
| SCHEMBL14677574 | 0.84 | LMNA (0.62) | POLBHPGDALDH1A1HSPB1TDP1 | |
| SCHEMBL31090851 | 0.84 | LMNA (0.62) | POLBHPGDALDH1A1HSPB1TDP1 | |
| SCHEMBL9497260 | 0.84 | L3MBTL1 (0.55) | POLBHPGDL3MBTL1ALDH1A1LTA4H | |
| SCHEMBL640851 | 0.84 | L3MBTL1 (0.51) | POLBHPGDL3MBTL1ALDH1A1LTA4H | |
| SCHEMBL1340465 | 0.84 | POLB (0.56) | POLBHPGDL3MBTL1ALDH1A1TDP1 | |
| SCHEMBL1283885 | 0.83 | HSPB1 (0.67) | POLBHPGDL3MBTL1ALDH1A1LTA4H | |
| SCHEMBL31090831 | 0.82 | MAPT (0.60) | POLBHPGDALDH1A1TDP1NPC1 | |
| SCHEMBL10588184 | 0.82 | MAPT (0.60) | POLBHPGDALDH1A1TDP1NPC1 | |
| SCHEMBL238962 | 0.81 | L3MBTL1 (0.62) | POLBHPGDL3MBTL1ALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936138-B | Heterobicyclic compounds as EP4 receptor antagonists | 深圳市原力生命科学有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111936138-A | Heterobicyclic compounds as EP4 receptor antagonists | 深圳市原力生命科学有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019152982-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 ANTAGONISTS | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2019-08-08 | — | — | WO | disclosed |
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1960347-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | Sterix Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | POLB 3790/4885HPGD 2590/4885L3MBTL1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.